Joint Formulary & PAD

Mirtazapine - Depression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Oro-dispersible tablets
  • Tablets
Associated Icons :
Restrictions / Comments :
 

Status 2

Non Formulary
Formulations :
  • Oral solution
Associated Icons :
Restrictions / Comments :
Important

Liquid formulation is not cost effective; consider orodispersible tablets.

PAD Profile

ChemicalSubstance :
Mirtazapine
Indication :
Depression
Group Name :
Keywords :
Tetracyclic antidepressants
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Mirtazapine is used to treat.

  • No records returned.

Committee Recommendations (1)

GENERIC Mirtazapine has been considered by the PCN and has been assigned a GREEN traffic light status. NOTE - the branded product, Zispin, was considered BLACK at the PCN in May 2017. Note - The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD. Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries